Bristol-Myers Squibb Company (BMY)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	8,025,000	8,285,000	7,963,000	7,311,000	6,327,000	6,677,000	6,617,000	6,251,000	6,994,000	-5,405,000	-5,079,000	-6,219,000	-9,015,000	-44,000	-563,000	954,000	3,439,000	5,655,000	6,203,000	5,144,000
Revenue (ttm)	US$ in thousands	45,006,000	44,935,000	45,187,000	45,848,000	46,159,000	46,738,000	47,144,000	46,960,000	46,385,000	45,468,000	44,384,000	42,810,000	42,518,000	39,395,000	34,862,000	31,006,000	26,145,000	24,173,000	23,857,000	23,288,000
Net profit margin		17.83%	18.44%	17.62%	15.95%	13.71%	14.29%	14.04%	13.31%	15.08%	-11.89%	-11.44%	-14.53%	-21.20%	-0.11%	-1.61%	3.08%	13.15%	23.39%	26.00%	22.09%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $8,025,000K ÷ $45,006,000K
= 17.83%

The net profit margin of Bristol-Myers Squibb Co. has shown a positive trend over the past eight quarters, indicating the company's ability to generate profit from its revenue. The net profit margin has steadily increased from 13.31% in Q1 2022 to 17.83% in Q4 2023, with occasional fluctuations along the way.

This improvement suggests that Bristol-Myers Squibb Co. has been effectively managing its expenses and operational costs relative to its revenue. A higher net profit margin indicates that the company is more efficient at converting revenue into profit after accounting for all costs.

Overall, the increasing trend in the net profit margin reflects positively on Bristol-Myers Squibb Co.'s financial performance and profitability in recent quarters.